Marco Basiricò

515 total citations
16 papers, 239 citations indexed

About

Marco Basiricò is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Marco Basiricò has authored 16 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Marco Basiricò's work include CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Marco Basiricò is often cited by papers focused on CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Marco Basiricò collaborates with scholars based in Italy, Austria and Belarus. Marco Basiricò's co-authors include Massimo Aglietta, Dario Sangiolo, Loretta Gammaitoni, Federica Capozzi, Ymera Pignochino, Giovanni Grignani, Carmine Dell’Aglio, Lorenzo D’Ambrosio, Marco Soster and Serena Marchiò and has published in prestigious journals such as Clinical Cancer Research, Annals of Oncology and British Journal of Haematology.

In The Last Decade

Marco Basiricò

16 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Basiricò Italy 8 117 89 75 50 33 16 239
Jieer Ying China 8 146 1.2× 99 1.1× 56 0.7× 34 0.7× 62 1.9× 22 270
Sook Kyung South Korea 8 104 0.9× 105 1.2× 65 0.9× 35 0.7× 50 1.5× 29 229
Shingo Togano Japan 10 107 0.9× 124 1.4× 60 0.8× 50 1.0× 72 2.2× 27 256
Qinghai Ji China 9 65 0.6× 83 0.9× 50 0.7× 66 1.3× 35 1.1× 22 240
Yaozhen Pan China 7 91 0.8× 176 2.0× 44 0.6× 46 0.9× 92 2.8× 22 284
Zhengfu Fan China 11 167 1.4× 142 1.6× 155 2.1× 27 0.5× 71 2.2× 34 347
Kunli Du China 11 121 1.0× 122 1.4× 46 0.6× 29 0.6× 72 2.2× 25 269
Liran Zhou United States 8 100 0.9× 213 2.4× 64 0.9× 44 0.9× 72 2.2× 10 324
Jianpei Liu China 10 206 1.8× 90 1.0× 65 0.9× 108 2.2× 40 1.2× 20 346
Judit López‐Luque Spain 8 95 0.8× 179 2.0× 56 0.7× 80 1.6× 70 2.1× 8 368

Countries citing papers authored by Marco Basiricò

Since Specialization
Citations

This map shows the geographic impact of Marco Basiricò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Basiricò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Basiricò more than expected).

Fields of papers citing papers by Marco Basiricò

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Basiricò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Basiricò. The network helps show where Marco Basiricò may publish in the future.

Co-authorship network of co-authors of Marco Basiricò

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Basiricò. A scholar is included among the top collaborators of Marco Basiricò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Basiricò. Marco Basiricò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Massa, Annamaria, Caterina Peraldo‐Neia, Chiara Varamo, et al.. (2025). Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Cancers. 17(1). 132–132. 1 indexed citations
2.
Petti, Consalvo, et al.. (2024). Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer. Journal of Translational Medicine. 22(1). 1100–1100. 4 indexed citations
3.
Petti, Consalvo, Sabrina Arena, Francesco Sassi, et al.. (2023). Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient. Frontiers in Oncology. 13. 1130852–1130852. 1 indexed citations
4.
Massa, Annamaria, Caterina Peraldo‐Neia, Chiara Varamo, et al.. (2022). Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Frontiers in Oncology. 12. 771418–771418. 4 indexed citations
5.
Basiricò, Marco, et al.. (2022). Off‐label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center. Pediatric Blood & Cancer. 70(3). e30148–e30148. 1 indexed citations
6.
Circosta, Paola, Susanna Gallo, Lidia Giraudo, et al.. (2022). Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers. British Journal of Haematology. 200(1). 64–69. 9 indexed citations
7.
Lombardi, Pasquale, Caterina Peraldo‐Neia, Alessandro Bonzano, et al.. (2022). Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT). Oncology Reports. 49(2). 9 indexed citations
8.
Pignochino, Ymera, Giovanni Crisafulli, G Giordano, et al.. (2021). PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers. 13(24). 6295–6295. 2 indexed citations
9.
Peraldo‐Neia, Caterina, Annamaria Massa, Marco Basiricò, et al.. (2021). A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. Cancers. 13(9). 2051–2051. 10 indexed citations
10.
Merlano, Marco, Cristina Granetto, Vincenzo Ricci, et al.. (2021). Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. Vaccines. 9(3). 235–235. 3 indexed citations
11.
Lombardi, Pasquale, Ilaria Depetris, Alessandro Bonzano, et al.. (2019). Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312). Annals of Oncology. 30. v222–v223. 1 indexed citations
12.
Varamo, Chiara, Caterina Peraldo‐Neia, Paola Ostano, et al.. (2019). Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers. 11(4). 519–519. 24 indexed citations
13.
Sanlorenzo, Martina, Igor Vujic, Mauro Novelli, et al.. (2018). BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody. Clinical Cancer Research. 24(14). 3377–3385. 30 indexed citations
14.
Mesiano, Giulia, Giovanni Grignani, Erika Fiorino, et al.. (2018). Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. OncoImmunology. 7(11). e1465161–e1465161. 23 indexed citations
15.
Pignochino, Ymera, Carmine Dell’Aglio, Simona Inghilleri, et al.. (2015). The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 15(1). 374–374. 26 indexed citations
16.
Pignochino, Ymera, Carmine Dell’Aglio, Marco Basiricò, et al.. (2013). The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research. 19(8). 2117–2131. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jieer Ying Breakdown of academic impact, for papers by Sook Kyung Breakdown of academic impact, for papers by Shingo Togano Breakdown of academic impact, for papers by Qinghai Ji Breakdown of academic impact, for papers by Yaozhen Pan Breakdown of academic impact, for papers by Zhengfu Fan Breakdown of academic impact, for papers by Kunli Du Breakdown of academic impact, for papers by Liran Zhou Breakdown of academic impact, for papers by Jianpei Liu Breakdown of academic impact, for papers by Judit López‐Luque
Rankless by CCL
2026